P. Pantazis et al., CYTOTOXIC EFFICACY OF 9-NITROCAMPTOTHECIN IN THE TREATMENT OF HUMAN-MALIGNANT MELANOMA-CELLS IN-VITRO, Cancer research, 54(3), 1994, pp. 771-776
In a recent study, we showed that the plant alkaloid camptothecin (CPT
) and its derivatives 9-nitro-CPT (9NC) and 9-amino-CPT (9AC) inhibit
growth of both human melanocytes (MEL cells) and their malignant count
erparts, malignant melanoma (BRO) cells in vitro. This growth inhibiti
on was accompanied by an increase in the size of BRO cells followed by
death, whereas cell size increase and death were not observed in MEL
cells. In this study, we have extended those investigations to identif
y parameters and factors that can modulate the cytotoxic action of 9NC
against BRO cells in culture. MEL cells treated with 9NC accumulate a
t the S/G2 boundary of the cell cycle and remain there for a prolonged
period of time with only a small number of cells dying by apoptosis.
The extent of accumulation correlates with the length of 9NC treatment
and/or 9NC concentration in the cell culture. Furthermore, treatment
with low 9NC concentrations for a prolonged time or treatment with hig
h drug concentrations results in a fraction of MEL cells with hyperdip
loidy. In contrast, 9NC-treated BRO cells are arrested in the S phase
before they die by apoptosis. Interestingly, lower 9NC concentrations
are more effective than higher concentrations in inducing apoptosis. O
nce 9NC initiates the process of apoptosis in BRO cells, these cells a
re irrevocably committed to it and continue to die even after removal
of the drug from the culture. The drug effectiveness to induce apoptos
is correlates with the stage of the S phase, in which it affects DNA r
eplication, with late stages resulting in higher numbers of apoptotic
cells. Finally, although various 9NC concentrations result in inhibiti
on of BRO cell proliferation, higher 9NC concentrations produce more e
nlarged BRO cells as assessed by microscopy. Taken together, these obs
ervations provide useful information for clinical application of 9NC a
s a chemotherapeutic agent against malignant melanoma.